Recce Pharmaceuticals Ltd has received positive Phase II clinical trial results for RECCE® 327 Topical Gel (R327G) in treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including Diabetic Foot Infections (DFI). The study achieved a 93% primary efficacy endpoint over 14 days, with an interim response rate of 86% at seven days. No serious adverse events were reported. These results support Recce’s upcoming Phase III registrational study for DFI in Indonesia, which has been approved by the Indonesian Drug and Food Regulatory Authority. An interim analysis is expected in 2025, with full trial completion anticipated by the end of the year. Recce will also advance to a Phase III trial for ABSSSI and DFI in Australia. Recce aims for an accelerated commercialisation pathway by 2026. The global ABSSSI treatment market was valued at US$7.3 billion in 2018 and is projected to reach US$26 billion by 2032. The trial followed FDA standards, using recognised diagnostic tools to assess treatment efficacy. The findings reinforce R327G’s potential as a broad-spectrum anti-infective to address antimicrobial resistance. #ReccePharmaceuticals, #ClinicalTrials, #Phase2Trial, #Antibiotics, #AntimicrobialResistance, #SkinInfections, #DiabeticFootInfections, #MedicalResearch, #Pharmaceuticals, #Healthcare, #DrugDevelopment, #FDAApproval, #Biotech, #MedicalInnovation, #WoundCare, #R327G, #BacterialInfections, #PharmaIndustry, #AustraliaHealthcare, #GlobalHealth